

News Release

November 17, 2023

FOR IMMEDIATE RELEASE

Biocure Technology Inc ("CURE") Announces Shares for Debt Transaction

VANCOUVER, British Columbia, November 15, 2023 -- Biocure Technology Inc. ("CURE" or the "Company") (CSE:CURE) announces that it has entered into agreements dated for reference October 31, 2023 with thirteen creditors to settle outstanding debts in the aggregate amount of CAD \$619,844.26 (the "Debts") through the issuance of an aggregate of 12,396,885 common shares (the "Settlement Shares") at a deemed price of 5 cents per share. An aggregate of CAD\$292,875.00 is being settled with three directors of the Company and will constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company expects to rely on exemptions from the formal valuation and minority approval requirements of MI 61-101 as the fair market value of the Debts in so far as the Debts involve interested parties does not exceed 25% of the Company's market capitalization. The Settlement Shares will be subject to applicable restrictions under securities laws.

The purpose of the debt settlement is to improve the Company's working capital position as it seeks to move forward with its previously announced transaction (the "Transaction") with Atriva Therapeutics GmbH ("Atriva") (see press release dated September 18, 2023). The Company and Atriva continue to complete their due diligence activities and have agreed to extend the time to complete a definitive agreement in respect of the proposed Transaction from November 30, 2023 to January 31, 2024.

ON BEHALF OF THE BOARD OF DIRECTORS

/S/ "KONSTANTIN LICHTENWALD" CFO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7146, or info@biocuretech.com

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.